JAK Inhibitors and the Evolving Treatment Landscape in Atopic Dermatitis and Alopecia Areata

Program Description

Though topical and systemic therapies are standard for the management of atopic dermatitis (AD) and alopecia areata (AA), many patients continue to experience substantial adverse effects associated with these therapies as well as significant disease burden affecting overall quality of life. Recently approved Janus kinase (JAK) inhibitors offer a new mechanism of action to address autoimmune diseases such as AD and AA. As clinical data surrounding the use of JAK inhibitors continue to emerge, managed care pharmacists will be tasked with formulary decisions and evaluating the cost-effectiveness of these new agents as part of treatment paradigms for AD and AA. This webinar will review efficacy and cost data for JAK inhibitors with information regarding dosing and considerations about specific adverse effects of therapy, such as risk for infections. In addition to examining recent clinical data, the role of managed care pharmacists in using evidence-based protocols to identify patient response to therapy and facilitate access to cost-effective care for patients with AD and AA will be discussed.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: December 20, 2022
Expiration date: February 20, 2023

Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Investigate the commonalities in atopic dermatitis (AD) and alopecia areata (AA) as chronic, inflammatory skin diseases and the burden of these disorders on the quality of life for patients
• Examine the recent clinical data and place in therapy for new and emerging JAK inhibitors for the treatment of AD and AA
• Identify the managed care considerations when evaluating new agents and integrating evidence-based treatment protocols for patients with AD and AA

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-593-L01-P. The activity is available for CE credit through February 20, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Dana McCormick, RPh, FAMCP

Medical Writer

Ashley Walsh, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle C. Carlson, PharmD; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms